<?xml version="1.0" encoding="utf-8"?>
<recommendedContent xmlns="http://api.mspoke.com">
    <recommendedItem id="20100101_19_459"
                     title="Murtha Dead at 77"
                     score="0.014"
                     href="http://www.medpagetoday.com/Washington-Watch/Washington-Watch/tb/18388?impressionId=1265747712767"
                     
      &lt;p&gt;Representative John P. Murtha (D-Pa.), 77, long-time chairman of the House Appropriations Subcommittee on Defense, died yesterday afternoon from complications following a planned laparoscopic cholecystectomy, according to a statement from the congressman&apos;s office.&lt;/p&gt;
&lt;p&gt;He had been admitted to the intensive care unit at Virginia Hospital Center in Arlington on Jan. 31, days after surgeons at the National Naval Medical Center in Bethesda, Md., accidentally nicked his intestine during the operation, according to a report in &lt;em&gt;The Washington Post&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;In that same report, Rep. Bob Brady (D-Pa.), a close friend of Murtha&apos;s, said the congressman developed an infection and fever.&lt;/p&gt;
&lt;p&gt;Citing a request for privacy from the Murtha family and patient privacy laws, a spokesperson for the National Naval Medical Center declined to provide information on the operation.&lt;/p&gt;
&lt;p&gt;In a statement, Virginia Hospital Center said Murtha died &quot;despite aggressive critical care interventions.&quot;&lt;/p&gt;
&lt;p&gt;According to the American College of Surgeons, risks of laparoscopic cholecystectomy include bleeding, infection, injury to the bile duct, liver injury, numbness, hernia at the incision site, anesthesia complications, and puncture of the intestine.&lt;/p&gt;
&lt;p&gt;Death is extremely rare in healthy individuals, occurring in no more than one per 1,000 patients, according to the college.&lt;/p&gt;
&lt;p&gt;A 2009 Cochrane Review comparing laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis found no difference in mortality in 38 trials. No patients died in the laparoscopic group and only 0.09% died in the open group.&lt;/p&gt;
&lt;p&gt;Severe complications were reported in 2.2% of the laparoscopic patients and 6.8% of the open patients.&lt;/p&gt;
&lt;p&gt;Murtha had recently become the longest serving member of Congress in Pennsylvania state history.&lt;/p&gt;
&lt;p&gt;First elected in 1974, Murtha, a former Marine, was the first Vietnam War combat veteran to serve in Congress, and he served as an advocate for the military throughout his career. He was also a prominent critic of the Iraq War.&lt;/p&gt;
&lt;p&gt;Murtha is survived by his wife, Joyce, and three children.&lt;/p&gt;

    </recommendedItem>
    <recommendedItem id="20100101_19_277"
                     title="Liver Cell Culture System Might Test New HCV Drugs (CME/CE)"
                     score="0.003"
                     href="http://www.medpagetoday.com/InfectiousDisease/Hepatitis/tb/18133?impressionId=1265747712767"
                     
      &lt;p&gt;Researchers say they can now grow liver cells that maintain their functions long enough to test potential treatments for hepatitis C.&lt;/p&gt;
&lt;p&gt;The method uses so-called &quot;micropatterned co-cultures&quot; of primary human hepatocytes and supportive stroma, according to Sangeeta N. Bhatia, MD, PhD, of MIT, and colleagues.&lt;/p&gt;
&lt;p&gt;The co-cultures were able to support the entire life cycle of hepatitis C, including infection and replication, Bhatia and colleagues reported online in the &lt;em&gt;Proceedings of the National Academy of Sciences&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;Coupled with reporter systems, the co-cultures have &quot;potential as a high-throughput platform for simultaneous assessment of in vitro efficacy and toxicity&quot; of antiviral drugs, the researchers said.&lt;/p&gt;
&lt;p&gt;The lack of such a system has been a roadblock to testing potential treatments for the virus, which affects 130 million people around the world, the researchers noted in the journal.&lt;/p&gt;
&lt;p&gt;Recently, they added, researchers have been able to propagate the virus in human hepatoma cells, but those cells, among other issues, proliferate abnormally and have disturbed gene expression.&lt;/p&gt;
&lt;p&gt;To overcome those obstacles, the researchers turned to primary hepatocytes, which would make a better test system, except that they are notoriously hard to maintain in culture.&lt;/p&gt;
&lt;p&gt;To form the co-cultures, Bhatia and colleagues seeded multi-well plates with human hepatocytes, followed several hours later by murine fibroblasts.&lt;/p&gt;
&lt;p&gt;&quot;If you just put cells on a surface in an unorganized way, they lose their function very quickly,&quot; Bhatia said in a statement. &quot;If you specify which cells sit next to each other, you can extend the lifetime of the cells and help them maintain their function.&quot;&lt;/p&gt;
&lt;p&gt;In a series of experiments, Bhatia and colleagues found:&lt;ul&gt; &lt;li&gt;Pseudoparticles bearing the hepatitis C glycoproteins E1 and E2 were able to infect between 1% and 3% of the hepatocytes, but did not infect the fibroblasts.&lt;/li&gt; &lt;li&gt;A hepatitis C virus modified to express a fluorescent protein persistently replicated over a two-week period.&lt;/li&gt; &lt;li&gt;Infectious virus was found in the co-culture supernatant from four through 12 days after initial infection.&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;The researchers also tested some possible therapeutics, including antibodies against viral entry factors and viral protease inhibitors, and were able to show effects on replication of hepatitis C.&lt;/p&gt;
&lt;p&gt;They were also able to test two or more drugs simultaneously to show the feasibility of combination drug studies using the system.&lt;/p&gt;
&lt;p&gt;Although the system is &quot;an important step forward,&quot; Bhatia and colleagues said, the co-cultures have some limitations, including the relatively inefficient uptake of virus.&lt;/p&gt;
&lt;p&gt;But they concluded that the co-cultures have the potential to be a &quot;highly valuable system for studies of (hepatitis C) biology.&quot;&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;This study had support from the Greenberg Medical Research Institute, the Ellison Medical Foundation, the Starr Foundation, the Ronald A. Shellow Memorial Fund, the Richard Salomon Family Foundation, and the NIH. The researchers said they had no conflicts.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_201"
                     title="Viral Cause of Appendicitis Called Unlikely (CME/CE)"
                     score="-0.002"
                     href="http://www.medpagetoday.com/Surgery/GeneralSurgery/tb/18048?impressionId=1265747712767"
                     
      &lt;p&gt;The cause of appendicitis remains a mystery, according to a study that discounts flu and intestinal infection as candidates.&lt;/p&gt;
&lt;p&gt;Influenza&apos;s distinctive seasonal variations don&apos;t match appendicitis hospitalization rates, according to researchers led by Edward H. Livingston, MD, of the University of Texas Southwestern Medical Center in Dallas.&lt;/p&gt;
&lt;p&gt;Enteric infections and rotavirus showed trends that were likewise dissimilar to those of perforating and nonperforating appendicitis, the researchers reported in the January issue of the &lt;em&gt;Archives of Surgery&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;&quot;Most theories regarding the underlying causes of appendicitis rely on the notion that the appendix becomes obstructed,&quot; they wrote.&lt;/p&gt;
&lt;p&gt;However, a more complex explanation appears necessary, they said, citing studies suggesting that blockage by hard pieces of stool called fecaliths is rare and that intraluminal pressures become elevated only in late-stage disease as inflammation progresses.&lt;/p&gt;
&lt;p&gt;Viral infection has been proposed as one explanation.&lt;/p&gt;
&lt;p&gt;And apparent &quot;outbreaks&quot; of appendicitis have been described in epidemiologic studies, suggesting an infectious etiology, Livingston&apos;s group noted.&lt;/p&gt;
&lt;p&gt;&quot;Viral infection of the appendix could cause mucosal ulceration followed by secondary bacterial infection of the appendix,&quot; they wrote. &quot;Alternatively, viral disease could result in lymphoid hyperplasia of the appendix with resultant obstruction and mucosal injury followed by bacterial infection.&quot;&lt;/p&gt;
&lt;p&gt;To explore the viral etiology scenario, the researchers used the National Hospital Discharge Survey to measure disease incidence trends from 1970 to 2006 based on admissions for appendicitis, flu, rotavirus, and enteric infections.&lt;/p&gt;
&lt;p&gt;They found a decline in overall annual incidence of both nonperforating appendicitis and influenza until 1995, after which the incidence for both rose in parallel.&lt;/p&gt;
&lt;p&gt;Perforating appendicitis, on the other hand, slowly rose in incidence over the years without a U-shaped curve.&lt;/p&gt;
&lt;p&gt;The incidence of perforating appendicitis, in fact, did not correlate with that of nonperforating appendicitis or any infectious disease studied.&lt;/p&gt;
&lt;p&gt;This suggested that &quot;perforated appendicitis has causative factors that are more complex than the simple delay in treating acute appendicitis,&quot; the researchers said.&lt;/p&gt;
&lt;p&gt;Rebecca C. Britt, MD, of Eastern Virginia Medical School in Norfolk, Va., commented that this was perhaps the most important implication of the study  --  that perforating and nonperforating appendicitis may be separate entities.&lt;/p&gt;
&lt;p&gt;Her critique accompanying the &lt;em&gt;Archives&lt;/em&gt; paper cautioned that further investigation is &quot;definitely warranted.&quot;&lt;/p&gt;
&lt;p&gt;But if confirmed, management patterns could shift, the researchers said.&lt;/p&gt;
&lt;p&gt;&quot;This has important clinical ramifications since appendectomy is generally performed as an emergency operation for fear of causing a perforation if treatment is delayed,&quot; they wrote.&lt;/p&gt;
&lt;p&gt;For nonperforating appendicitis, the year-to-year association with influenza was discounted by the lack of within-year correlation.&lt;/p&gt;
&lt;p&gt;Appendicitis occurred throughout the year, with a &quot;slight tendency&quot; to occur more often in summer months whereas the flu was largely limited to winter.&lt;/p&gt;
&lt;p&gt;Furthermore, appendicitis is predominantly a disease of the young, while influenza disproportionately affects the older population, &quot;which goes against influenza as a proximate agent,&quot; Britt added.&lt;/p&gt;
&lt;p&gt;&quot;While perhaps influenza plays a role in the development of appendicitis by sensitizing the immune system to another viral agent, there remains no clear evidence that it is a causative agent for appendicitis,&quot; she wrote.&lt;/p&gt;
&lt;p&gt;Rotavirus infection also peaked in the winter months, without an apparent association with appendicitis incidence.&lt;/p&gt;
&lt;p&gt;Intestinal infection incidence matched the fairly even distribution of appendicitis throughout the year, but had a propensity to be higher in winter months rather than during the summer as was the case with appendicitis.&lt;/p&gt;
&lt;p&gt;Overall and peak hospital admission rates for intestinal infection began a yearly rise in 1989 and have been steadily increasing, which also did not match trends in appendicitis.&lt;/p&gt;
&lt;p&gt;Britt cautioned that the study relied on hospital discharge data, which is not likely to be a complete picture of incidence for viral illness because the vast majority of cases do not require hospitalization and many are not treated at all.&lt;/p&gt;
&lt;p&gt;&quot;Certainly this makes comparison onerous,&quot; she said.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The researchers reported no conflicts of interest. Britt reported no conflicts of interest.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_216"
                     title="Novel Treatment Cuts Recurrence of &lt;em&gt;C. difficile&lt;/em&gt; (CME/CE)"
                     score="-0.002"
                     href="http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/tb/18067?impressionId=1265747712767"
                     
      &lt;p&gt;Adding two investigational monoclonal antibodies to standard antibiotics reduced the rate of recurrent &lt;em&gt;Clostridium difficile &lt;/em&gt;infection, a phase II randomized controlled trial showed.&lt;/p&gt;
&lt;p&gt;Patients who received a single infusion with the two monoclonal antibodies were significantly less likely to have a recurrence through 84 days of follow-up than those who received placebo (7% versus 25%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001), according to Israel Lowy, MD, PhD, of Medarex in Princeton, N.J., and colleagues.&lt;/p&gt;
&lt;p&gt;Adverse events occurred at similar rates in the two groups, the researchers reported in the Jan. 21 &lt;em&gt;New England Journal of Medicine.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Medarex is a subsidiary of Bristol-Myers Squibb focused on developing fully human antibody-based therapies.&lt;/p&gt;
&lt;p&gt;&quot;The trial results are impressive,&quot; Lorraine Kyne, MD, MPH, of University College Dublin, wrote in an accompanying editorial.&lt;/p&gt;
&lt;p&gt;Although monoclonal antibodies probably would not be used as first-line treatment, she said, &quot;this novel nonantibiotic approach to secondary prevention is likely to offer hope to physicians and patients battling &lt;em&gt;C. difficile&lt;/em&gt; infection.&quot;&lt;/p&gt;
&lt;p&gt;Agreeing was Neil Fishman, MD, of the University of Pennsylvania, who called the findings &quot;very encouraging and very exciting&quot; in an interview.&lt;/p&gt;
&lt;p&gt;However, he noted that the safety of the treatment would have to be established in a much higher number of patients.&lt;/p&gt;
&lt;p&gt;The proper place for the antibody therapy in the management of &lt;em&gt;C. difficile&lt;/em&gt; needs to be established in future studies as well, said Fishman, who is also chair of the antimicrobial resistance work group for the Infectious Diseases Society of America.&lt;/p&gt;
&lt;p&gt;Whether it should be administered during a first episode or at first recurrence is an open question, he said, and the answer will depend both on phase III results and cost, which tends to be high for monoclonal antibody therapies.&lt;/p&gt;
&lt;p&gt;Still, he said, &quot;All disclaimers aside, I think this is a very significant, important study and an important new development in the management of &lt;em&gt;C. difficile&lt;/em&gt;.&quot;&lt;/p&gt;
&lt;p&gt;Lowy&apos;s group wrote in the journal that new therapies are needed to manage &lt;em&gt;C. difficile&lt;/em&gt;, which is increasing in prevalence and severity.&lt;/p&gt;
&lt;p&gt;Some 15% to 30% of patients will have a recurrence despite antibiotic treatment, which itself puts patients at risk for &lt;em&gt;C. difficile&lt;/em&gt; diarrhea or colitis. Broad-spectrum antibiotics knock the infection down but do not allow for the re-establishment of normal bowel flora.&lt;/p&gt;
&lt;p&gt;In addition, a hypervirulent strain  --  called BI/NAP1/027 --  has emerged in several large, deadly outbreaks in the U.S., Canada, and Europe. (See &lt;a href=&quot;http://www.medpagetoday.com/InfectiousDisease/PublicHealth/2254&quot; mce_href=&quot;http://www.medpagetoday.com/InfectiousDisease/PublicHealth/2254&quot; target=&quot;_blank&quot;&gt;Virulent Strain of &lt;em&gt;C. Difficile&lt;/em&gt; Called Cause of Diarrhea Outbreaks&lt;/a&gt;)&lt;/p&gt;
&lt;p&gt;The two fully human, monoclonal antibodies evaluated by Lowy&apos;s group  --  one each against &lt;em&gt;C. difficile&lt;/em&gt; toxins A (CDA1) and B (CDB1)  --  showed efficacy in a hamster model and safety in healthy people.&lt;/p&gt;
&lt;p&gt;To further establish safety and efficacy, the researchers enrolled 200 patients with &lt;em&gt;C. difficile&lt;/em&gt; infection at 30 sites in the U.S. and Canada and randomized half to receive the antibodies and half to placebo.&lt;/p&gt;
&lt;p&gt;The antibodies were given together in a single infusion, both at a dose of 10 mg/kg.&lt;/p&gt;
&lt;p&gt;All patients were also receiving either metronidazole or vancomycin.&lt;/p&gt;
&lt;p&gt;In the antibody group, all cases of recurrence within 84 days of infusion occurred in patients who had been hospitalized during their initial episode.&lt;/p&gt;
&lt;p&gt;Echoing the primary finding, the rate of recurrence was significantly lower following the antibody infusion among the subgroup of patients who had had more than one previous episode of &lt;em&gt;C. difficile&lt;/em&gt; infection (7% versus 38%, &lt;em&gt;P&lt;/em&gt;=0.006).&lt;/p&gt;
&lt;p&gt;The recurrence rate also tended to be lower in the antibody group among patients who had the epidemic BI/NAP1/027 strain (8% versus 32%), although the difference did not reach statistical significance (&lt;em&gt;P&lt;/em&gt;=0.06).&lt;/p&gt;
&lt;p&gt;During the initial episode, the antibody treatment did not shorten the length of hospitalization or the time to resolution or severity of diarrhea compared with placebo.&lt;/p&gt;
&lt;p&gt;The antibodies were not immunogenic.&lt;/p&gt;
&lt;p&gt;Safety from the monoclonal antibody infusion was not a concern. Adverse events during infusion or within the next two hours occurred in 15 patients in the antibody group and 10 in the placebo group. All were mild to moderate, with headache the most common.&lt;/p&gt;
&lt;p&gt;During follow-up, at least one serious adverse event was reported by 18 patients in the antibody group and 28 in the placebo group, a difference that was not statistically significant (&lt;em&gt;P&lt;/em&gt;=0.09).&lt;/p&gt;
&lt;p&gt;There were 15 deaths during the study  --  seven in the antibody group and eight in the placebo group. None was attributed to the study drug.&lt;/p&gt;
&lt;p&gt;Lowy stressed that larger studies are needed to confirm the findings.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was supported by MassBiologics and Medarex, which employs two of the study authors.&lt;/p&gt;&lt;p&gt;Lowy and one of his co-authors reported being employees of Medarex and having an equity interest in the company. Lowy reported being named as a co-inventor on relevant patents with all rights or royalties assigned to Medarex and having an equity interest in Merck. His co-authors reported being named as co-inventors on relevant patents and sharing a partial interest in them, and having relationships with MassBiologics, Medarex, Robert Michael Associates, ViroPharma, GOJO Industries, Salix, Schering-Plough, Cepheid, Merck, TheraDoc, Optimer, and Genzyme.&lt;/p&gt;&lt;p&gt;Kyne reported receiving salary support from a Clinician Scientist Award from the Health Research Board, Ireland.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_183"
                     title="Gastric Bypass Extends Life for Most Patients (CME/CE)"
                     score="-0.003"
                     href="http://www.medpagetoday.com/PrimaryCare/Obesity/tb/18020?impressionId=1265747712767"
                     
      &lt;p&gt;For most patients in most categories, bariatric surgery increases life expectancy, according to a new mathematical model.&lt;/p&gt;
&lt;p&gt;Only when short-term mortality following bariatric surgery is expected to be high or the likelihood of success is low will the procedure fail to improve life expectancy, researchers reported in the January &lt;em&gt;Archives of Surgery&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;Computer modeling predicted that a hypothetical &quot;base case&quot; patient  --  a 42-year-old woman with a body mass index of 45  --  would gain 2.95 years of additional survival following bariatric surgery, according to Daniel P. Schauer, MD, of the University of Cincinnati, and colleagues.&lt;/p&gt;
&lt;p&gt;Surgery failed to be beneficial in the model only when 30-day mortality reached 9.5% or the likelihood that surgery would not add life-years was 2% or less, they found.&lt;/p&gt;
&lt;p&gt;Baseline 30-day mortality in the model was 0.2%, and the baseline efficacy of surgery in extending life expectancy was 53%.&lt;/p&gt;
&lt;p&gt;&quot;While not all patients are guaranteed a good outcome, our model indicates that gastric bypass increases life expectancy for most patient subgroups,&quot; they concluded.&lt;/p&gt;
&lt;p&gt;Their analysis was based on a Markov decision model using published data to estimate 30-day mortality following bariatric surgery and the efficacy of surgery in reducing long-term death rates.&lt;/p&gt;
&lt;p&gt;The latter had two components: reduction in excess mortality associated with obesity, and research data on long-term mortality following bariatric surgery.&lt;/p&gt;
&lt;p&gt;Excess mortality estimates came from National Health Interview Survey data on some 400,000 participants from 1991 to 1996 linked to the National Death Index. Inputs on surgery efficacy were derived from a 2007 study of nearly 8,000 patients who had undergone gastric bypass and the same number of medically treated or untreated obese controls.&lt;/p&gt;
&lt;p&gt;That study found that the procedure cut death rates by half during about seven years of follow-up. (See &lt;a href=&quot;http://www.medpagetoday.com/PrimaryCare/Obesity/6480&quot; mce_href=&quot;http://www.medpagetoday.com/PrimaryCare/Obesity/6480&quot; target=&quot;_blank&quot;&gt;Missing Link Found: Bariatric Surgery Reduces Mortality&lt;/a&gt;)&lt;/p&gt;
&lt;p&gt;Schauer and colleagues obtained rates of inhospital mortality following bariatric surgery from the 2005 National Inpatient Survey, then multiplied them by three to estimate 30-day mortality.&lt;/p&gt;
&lt;p&gt;The researchers explained that according to earlier research, inhospital death rates typically underestimate 30-day mortality by a factor of two to three.&lt;/p&gt;
&lt;p&gt;Their threefold correction factor represents &quot;a conservative estimate that biases the model against gastric bypass surgery,&quot; they wrote.&lt;/p&gt;
&lt;p&gt;Schauer and colleagues tested this correction factor and other aspects of the model in sensitivity analyses.&lt;/p&gt;
&lt;p&gt;The biggest gains in life expectancy occurred in younger women with relatively high BMI values, the model showed.&lt;/p&gt;
&lt;p&gt;The age effect was less important than BMI at the time of surgery. A 35-year-old woman with BMI of 45 would gain about 3.2 years of extra life, whereas at 55, a similarly obese woman would gain about 2.5 extra years.&lt;/p&gt;
&lt;p&gt;But a 35-year-old woman with BMI of 55 could expect to live five more years with surgery, the model indicated.&lt;/p&gt;
&lt;p&gt;Men in general derived less survival benefit from bariatric surgery, particularly with advancing age at the time of the procedure.&lt;/p&gt;
&lt;p&gt;At 35, the difference in life expectancy gained was roughly 10%, but by age 75 it had grown to about 50%.&lt;/p&gt;
&lt;p&gt;The sensitivity analyses found that relatively large changes in most parameters used in the model did not affect the overall results substantially.&lt;/p&gt;
&lt;p&gt;The effect of 30-day mortality on whether or not surgery was beneficial for long-term survival was related to BMI and gender.&lt;/p&gt;
&lt;p&gt;For women with a BMI of 40, 30-day mortality of more than 5% would mean surgery was not helpful, but short-term mortality had to exceed 15% for surgery not to be preferable for those with BMI of 55 or more. These thresholds were about 10% higher for men.&lt;/p&gt;
&lt;p&gt;The efficacy of surgery in reducing mortality was less important for older men, the analysis also showed. A 75-year-man with a BMI of 35 could expect only a very slight gain in life span  --  perhaps one or two months.&lt;/p&gt;
&lt;p&gt;&quot;Younger patients have lower surgical risk and more time over which to realize the benefits of surgery. For older patients, the gain is smaller, and for some, gastric bypass surgery will decrease life expectancy,&quot; Schauer and colleagues wrote.&lt;/p&gt;
&lt;p&gt;However, they identified several potentially serious limitations to the analysis.&lt;/p&gt;
&lt;p&gt;The study of long-term mortality following bariatric surgery was conducted at a single center and was not randomized. Additionally, long-term complications, such as need for repeat surgery, were not addressed in the model. Certain other risks that might be heightened after bariatric surgery were excluded as well, and quality of life was not modeled.&lt;/p&gt;
&lt;p&gt;&quot;The decision analysis presented here is a step forward in understanding optimal patient selection but also highlights some of the areas for which better data are needed,&quot; the researchers wrote.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The National Institute of Diabetes and Digestive and Kidney Diseases funded the study.&lt;/p&gt;&lt;p&gt;No potential conflicts of interest were reported.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
</recommendedContent>
